In osteosarcomas, high SOX2 expression has been associated with more aggressiveness, increased metastasis, chemotherapy resistance and poorer prognosis.10–13 Targeting SOX2 may eradicate the cancer stem cell population that is responsible for tumor recurrence after initial treatment. This evidence concerns the gene SOX2 and osteosarcoma.